Switching from Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease is Feasible and Uneventful

Lisa Gervais, Luke L McLean, Michelle L Wilson, Carol Cameron, Lee Curtis, Vikki Garrick, Kat Armstrong, Rachel Tayler, Paul Henderson, Richard Hansen, Iain Chalmers, David C Wilson, Richard K Russell

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Switching from Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease is Feasible and Uneventful'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology